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Abstract
Background: The Quality of Life of Short Stature Youth (QoLISSY) questionnaire is a patient- and parent-reported
outcome measure assessing health-related quality of life (HRQOL) in short stature youth. This study evaluates the
psychometric properties of the QoLISSY questionnaire within a German prospective trial of short statured children
treated with human growth hormone (hGH).
Method: The instrument was administered to children with idiopathic growth hormone Deficiency (IGHD) and
small for gestational age (SGA) before and after 12 month of hGH treatment. Children with idiopathic short stature
(ISS) served as a reference group receiving no treatment. Psychometric testing included scale distribution
characteristics, reliability (internal consistency), criterion-and convergent validity (correlations with the generic
KIDSCREEN-Index, inter-correlations among QOLISSY subscales), known-group validity (treatment status, height SDS),
and responsiveness analysis (ability to detect change).
Results: One hundred fifty-two parents and 66 children/adolescents completed both HRQOL assessments. The
QoLISSY demonstrated good reliability with Cronbach’s alpha > .70. Moderate significant correlations between
QoLISSY domains and the KIDSCREEN-10 Index supported criterion validity. Statistically significant differences in
HRQOL were observed between treatment groups at baseline with children who were about to start treatment
reporting a significantly lower HRQOL compared to the children who will not receive treatment. No significant
differences were found between the level of short stature based on height SDS scores (≤ − 2 SDS, > − 2 SDS).
Furthermore, the instrument detected significant changes in HRQOL between the treated and the untreated group
in patient-reports.
Conclusions: In conclusion, the scales showed satisfactory reliability, adequate validity and ability to detect change in
self-reported HRQOL within GH treatment. Findings support QoLISSY’s further use in clinical trials, offering the opportunity
to adequately assess HRQOL from the patients’ and caregivers’ perspective to improve patient-centered care.
Keywords: Health-related quality of life, Patient-reported outcome, Idiopathic growth hormone deficiency, Small for
gestational age, Idiopathic short stature, Human growth hormone treatment
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Background
In recent years, health-related quality of life (HRQOL)
has become an important health outcome indicator for
use in clinical trials as well as in epidemiological analysis
and health service research. Furthermore, it received in-
creased recognition as a relevant health indicator in chil-
dren with chronic conditions [1]. Using patient-reported
outcome (PRO) instruments to assess HRQOL can high-
light patients’ unmet needs, improve communication be-
tween clinicians and patients, capture the individual and
societal impact of a disease, and provide additional infor-
mation about intervention outcomes directly from the
patient’s perspective. Hence, HRQOL instruments are
being increasingly used in adults and children to assess
information about the subjective perception of health
and to evaluate the effects of treatments from the pa-
tients’ and caregivers’ perspectives [2–7].
The multidimensional concept of HRQOL describes
the subjective perception of health status and includes
physical, social, emotional and mental domains of well-
being and functioning [2, 8]. In addition to generic
HRQOL instruments, covering the full range from excel-
lent to poor health, disease-specific measures are neces-
sary to capture the burden and experience of defined
health conditions [9–12]. Particularly when assessing
HRQOL in chronic and rare diseases, such as short stat-
ure in youth, generic PRO measures might be not sensi-
tive enough to detect aspects of diagnosis and treatment
that affect the patients’ HRQOL, underlining the need
for disease-specific measures [2, 7]. Assessments of
HRQOL in short stature youth have been conducted
using both generic and disease-specific instruments such
as the PedsQL Generic Core Scales [13, 14] and the
disease-specific Quality of Life of Short Stature Youth
(QoLISSY) questionnaire [3, 12, 15]. Although research
has shown that using a generic HRQOL instrument in
short stature children can detect differences in HRQOL
and psychosocial functioning when compared to chil-
dren with normal stature [13, 14, 16], it has been shown
that short stature-specific instruments can detect
changes in HRQOL in children who received treatment,
when compared to untreated children, while generic in-
struments were not sensitive enough to detect these
changes [17]. This finding underlines the importance of
assessing HRQOL in longitudinal studies with disease-
specific instruments, because if significant differences in
HRQOL are no longer detected at least one year after
children start treatment, then a positive effect of treat-
ment on HRQOL can be reasonably assumed.
Short stature is defined as a height being more than 2
standard deviations (SD) below the mean height of the
corresponding population [18, 19] and has been associ-
ated with lower HRQOL [20, 21]. In order to improve
patients’ height, the short statured children can be
treated with human growth hormone (hGH) within the
accepted medical indications [22–24]. According to the
European Medicine Agency (EMA) this treatment op-
tion is only available for defined diagnoses, including
idiopathic growth hormone deficiency (IGHD) and being
born small for gestational age (SGA), but not for chil-
dren with idiopathic short stature (ISS) [25]. Primary
clinical outcomes of hGH treatment such as the increase
in height have been complemented by HRQOL as a rele-
vant endpoint [26]. Results from studies examining the
effects of hGH treatment on HRQOL are contradictory;
some studies report an increase in HRQOL due to treat-
ment [17, 27], while others report no changes in
HRQOL [28]. Furthermore, the use of different assess-
ment approaches (generic and disease-specific) within
these studies makes a comparison quite challenging [29].
When evaluating the change of HRQOL in intervention
studies, the responsiveness (ability to detect change) of
HRQOL instruments is an important characteristic.
To examine if the condition-specific QoLISSY question-
naire is a valid, reliable and responsive disease-specific in-
strument that measures HRQOL of short stature youth in
a longitudinal trial setting and can be used as a health out-
come indicator of hGH interventions, this study aimed to
evaluate the psychometric performance of the QoLISSY
questionnaire within a prospective observational study.
Thus, reliability, validity and responsiveness to change
were investigated in a sample of children and adolescents
with IGHD and SGA at start and within 1-year after hGH
treatment, documenting HRQOL in untreated children/
adolescents with ISS for comparison purposes.
Methods
Participants and study procedure
After receiving ethical approval from the respective eth-
ics committees of the participating centers (medical
chambers of Hamburg, Saxon, Hessen, Nordrhein and
the ethics committees of the University Hospitals of Er-
langen – Nürnberg, Cologne, Magdeburg and Munich),
eleven pediatric endocrinologists from various children
hospitals and medical practices in Germany agreed to re-
cruit patients for the present study. Included were newly
diagnosed children and adolescents and their parents
with IGHD and SGA before hGH treatment was initi-
ated. Children diagnosed with ISS served as a reference
group in this study. Children aged 8–12 years and ado-
lescents with a late diagnosis > 13 years were invited to
complete HRQOL instruments. For the parent-report,
parents of children, 8–12 years and > 13 years were re-
cruited for the study as well as parents of younger chil-
dren aged 4–7 years. Participants were excluded from
the study if they were diagnosed with any other condi-
tion that results in short stature (e.g. skeletal dysplasia,
chromosomal abnormalities, etc.), if they did not meet
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the respective age groups, if they were cognitively im-
paired or had a lack of adequate linguistic competency
to complete HRQOL assessments. Informed consent
from all participants was obtained before the start of the
study. Sample size calculations, using the Software PASS
2008, suggested that with a power of 80% to detect
changes in the QoLISSY total score (sum of the scales
physical, social and emotional) and including drop outs
in the calculations, the desired sample size should in-
clude each N = 160 children/adolescents in the interven-
tion and control group and N = 240 parents. Children in
the intervention group (diagnosed with SGA or IGHD)
were treated with daily subcutaneous injections with
hGH, whereas children in the reference group (diag-
nosed with ISS) received no treatment.
The parents and their children were asked to provide
HRQOL assessments before the start of hGH treatment
(baseline, T0) and at 12 month after the start of treat-
ment (T1). The questionnaires were handed out to the
participants in the respective center and were completed
on-site at both points of measurement. Thereafter, the
staff sent the questionnaires by post to the study center
in Hamburg. In addition to HRQOL questionnaires,
sociodemographic and clinical data such as age, gender
body weight and height were assessed by a clinician at
both timepoints. Height standard deviation scores (SDS)
was calculated with the LMS formula [30] based on ref-
erence data by Kromeyer-Hausschild [31]. Children diag-
nosed with ISS not undergoing hGH treatment followed
the same procedure.
Measures
HRQOL was assessed with the generic KIDSCREEN-
10 index and with the condition-specific QoLISSY
questionnaire.
The QoLISSY questionnaire was developed in accord-
ance with the guidance on PRO instrument development
of the US Food and Drug Administration [32] within a
cross cultural study aiming to assess HRQOL in children
and adolescents with ISS and IGHD. The questionnaire
is available in self-report for short statured children and
adolescents aged 8–18 years and for parents of children
aged 4–18 years (observer-report). The instrument as-
sesses HRQOL in the core domains physical (6 items),
social (8 items) and emotional (8 items), which are
summed up in the total score (22 items). Additionally,
three domains measure predictors of quality of life (cop-
ing, 10 items; beliefs, 4 items and treatment, 14 items) in
child- and parent-report. The parent’s version contains
two supplementary domains that refer to the parent’s
worries about their child’s future (future, 5 items) and
the impact of the child’s condition on the parents’ well-
being (effects on parents, 11 items). The response scale
consists of a five-point Likert scale ranging from “not at
all/never” to “extremely/always”. Psychometric results
from the original QoLISSY study prove satisfactory reli-
ability with Cronbach’s ranging from α = .82 (coping
scale) to α = .92 (total QoL score) in self-report and from
α = .86 (physical scale) to α = .95 (total QoL score) in
parent-report [33]. Psychometric performance of the
QoLISSY questionnaire has also been proven to be satis-
factory in further cross-sectional validation studies in
the US, Italy, Belgium and in the Netherlands [34–37].
At present, QoLISSY has also been validated for use in
children being born small for gestational age (SGA) and
achondroplasia [38, 39].
The KIDSCREEN-10 index is a unidimensional generic
measure to assess the HRQOL in children and adoles-
cents (8–18 years) from the child- and parent perspec-
tive on a five-point Likert scale. Psychometric properties
of the index as assessed in a prior study with a sample
of children and adolescents within the original QoLISSY
study were satisfactory in self - and parent-reports with
good validity and reliability (Cronbach’s alpha in
child-report α = .81, proxy-report α = .80) [40, 41].
Statistical analysis
All data analyses were conducted using the Statistical
Package for the Social Sciences, v.21 [42]. The signifi-
cance level was set at p < .05 and all assessed data of the
participants was pseudonymized for the analysis. First,
descriptive statistics were calculated for sociodemo-
graphic and clinical variables. The homogeneity of sam-
ple characteristics across the diagnostic groups at
baseline was examined by χ2 tests (categorical variables)
or independent-samples analysis of variance (continu-
ous variables).
Raw QoLISSY scores were transformed into 0 to 100
scores with higher values representing higher HRQOL.
The QoLISSY total score was calculated by summing up
the core domains physical, social and emotional. Mean
scale scores were computed and missing data that were
random and less than 20% of the values were replaced
with the individual mean score for each variable.
Descriptive QoLISSY statistics were calculated on a
scale level at baseline (T0) and after 12 month after the
onset of hGH treatment (T1) for child- and parent-re-
port including mean (M), standard deviation (SD), skew-
ness, kurtosis and floor/ceiling effects. Floor and ceiling
effects were considered to be present if more than 15%
of respondents achieved the highest or lowest possible
score, respectively [43].
To evaluate the reliability of the QoLISSY scales,
Cronbach’s alpha coefficients (α) were calculated for
each scale at baseline and at T1 for both patient- and
parent reports, considering α > .70 as an indicator of
good internal consistency [44].
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The inter-rater reliability was examined at the individ-
ual and the group levels [45], by using, respectively,
intraclass correlation coefficients (ICC; two-way mixed
model, absolute agreement, 95% confidence interval
[CI]) and multivariate analyses of covariance (MAN-
COVA) for repeated measures, entering the rater (parent
vs. child) as the within-subject factor and children’s age,
gender, height deviation group and treatment status
(only at T1) as covariates. ICC reference values were:
ICC < .40 as poor agreement, ICC between .41 and .60 as
moderate agreement, ICC between .61 and .80 as good
agreement, and ICC > .81 as excellent agreement [46].
The criterion validity was examined by calculating Pear-
son correlation coefficients (r) between the QoLISSY
scales and the KIDSCREEN-10 Index at both points of
measurement for the child- and parent-report. Although
the KIDSCREEN instruments can be considered as gold
standard instruments to assess HRQOL in children and
adolescents, they measure HRQOL at a generic level,
while the QoLISSY questionnaire assesses HRQOL at a
disease-specific level; therefore, moderate positive correla-
tions (r > .30) were considered indicators of good criterion
validity [44]. To assess convergent validity as part of the
construct validity, inter-correlations between the QoLISSY
scales were calculated using Pearson’s correlation coeffi-
cient as well.
To examine known-groups validity, multivariate analyses
of covariance (MANCOVA) were performed at both meas-
urement points for the child- and parent-report to compare
the HRQOL dimensions across the treatment status (chil-
dren with IGHD or SGA who were treated vs. untreated
children with ISS) and height deviation groups of normal
stature (> − 2 SDS) vs. short stature (≤ − 2 SDS), while con-
trolling for children’s age. For the QoLISSY total score and
when multivariate effects were significant, univariate analyses
of covariance (ANCOVA) were performed to examine which
QoLISSY scales were significantly different between groups.
Finally, to test the responsiveness of the QoLISSY ques-
tionnaires to detect changes in HRQOL dimensions within
the course of hGH treatment, a repeated measures MAN-
COVA was performed. The measurement points (baseline
vs. T1) were entered as the within-subjects factor, while the
treatment status (children with IGHD or SGA who were
treated vs. untreated children with ISS) as the between-sub-
jects factor, and children’s age and time difference between
both measurement points as covariates. A repeated measures
ANCOVA was performed for the QoLISSY total score and
for the generic KIDSCREEN-10 Index, respectively. Further-
more, a repeated measures MANCOVA testing the HRQOL
changes from baseline and 1-year follow-up (T1) between
patients who reached normal height and patients with
current short stature at T1 was calculated. Children’s age
and time difference between both measurement points were
entered as covariates. Presented effect-size measures were
analyzed based on Cohen (1988), considering a small effect
when ŋp
2 ≥ .01, a medium effect when ŋp
2 ≥ .06, and a large
effect when ŋp
2 ≥ .14 [47].
In addition, Pearson’s correlation analysis between
height SDS increase (i.e, height SDS at T1 – height SDS
at baseline) and the change in the QoLISSY total score
(i.e., QoLISSY total score at T1 – QoLISSY total score at
baseline) were performed with child and parent data to
determine the relationship between height change and
HRQOL change.
Results
Sample description
A total of 154 participants were recruited at baseline, with
66 children/adolescents and 152 parents completing both
HRQOL assessments. Of these and with a drop-out rate
of 15.6% (N = 24), 130 participants also completed the
HRQOL assessments at T1 with 70 patient-reports and
126 parent-reports available. Since patients grow older
during the study process, more patient-reports were avail-
able at T1. The average time frame between the baseline
assessment and T1 ranged from 6 to 18month (M =
12.54, SD = 2.2). Clinical and sociodemographic sample
characteristics of the participants at both measurement
points are presented in Table 1. At baseline, SGA patients
were significantly younger than patients diagnosed with
IGHD or ISS (F(2) = 9.21, p < .01). This trend was contin-
ued at T1 with SGA patients being significantly younger
than patients diagnosed with ISS (F(2) = 6.74, p < .01). Fur-
thermore, SGA patients were significantly smaller at base-
line (F(2) = 12.74, p < .01) and at T1 (F(2) = 5.59, p < .01)
compared to patients with IGHD or ISS. With regard to
height SDS, patients with SGA and IGHD were signifi-
cantly the smallest compared to patients with ISS at base-
line (F(2) = 8.70, p < .01). Moreover, a significantly higher
percentage of patients with ISS had already reached a nor-
mal height by definition at baseline (SDS > − 2), compared
to children/adolescents with IGHD or SGA before treat-
ment (χ(2)
2 = 13.92, p < .01). At T1 there were no signifi-
cant differences in height SDS (F(2) = 7.58, p = .47) or in
height deviations groups (χ(2)
2 = .85, p = .65) across diag-
noses. Also, there were no significant differences in gender
(χ(2)
2 = 5.93, p = .052) or treatment length (F(2) = .516,
p = .59) across diagnoses groups.
Descriptive statistics and reliability
Most QoLISSY dimensions showed a slight skew to the
right, indicating a predisposition for high HRQOL (ran-
ging from 0 to 100, with higher values representing
higher HRQOL) in child- and parent-report at baseline
and T1 across all diagnoses groups. However, the
parent-reported coping and effects on parents scale at
baseline and the parent-reported treatment scale at T1
as well as the child-reported beliefs scale at T1, showed
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a slight skew to the left, indicating lower HRQOL. The
Cronbach’s alpha values were higher than α > .70, except
for the child-reported coping scale at T1 (α = .65), indicat-
ing good internal consistency for raters and assessment
points. Highest consistency was found in the total score
(α > .90). Considering the threshold of 15% of respondents
scoring at the lowest or highest possible categories, no
ceiling or floor effects were found for any of the patient-
or parent-reported QoLISSY scales (Table 2).
Regarding inter-rater reliability, the ICC values indicated
moderate parent-child agreement, except for the coping
scale and treatment subscale where a higher disagreement
of HRQOL assessment between children and parents was
found. At a group level, the MANCOVA for repeated
measures showed no significant multivariate differences
between raters at baseline, Pillai’s trace = .11, F(5, 47) = 1.19,
p = .33, ŋp
2 = .11, and at T1, Pillai’s trace = .30, F(6, 30) =
2.10, p = .08, ŋp
2 = .30. The univariate effects are presented
in Table 3. In addition, no significant multivariate effects
of the interaction between rater and children’s sex at
baseline (Pillai’s trace = .05, F(5, 47) = 0.44, p = .82, ŋp
2 = .05)
and T1 (Pillai’s trace = .32, F(6, 30) = 2.30, p = .06, ŋp
2 = .32),
children’s age at baseline (Pillai’s trace = .12, F(5, 47) = 1.33,
p = .27, ŋp
2 = .12) and T1 (Pillai’s trace = .30, F(6, 30) = 2.10,
p = .08, ŋp
2 = .30), height deviation group at baseline (Pil-
lai’s trace = .02, F(5, 47) = .21, p = .96, ŋp
2 = .02) and at T1
(Pillai’s trace = .20, F(6, 30) = 1.24, p = .31, ŋp
2 = .20), or
treatment status (T1), Pillai’s trace = .24, F(6, 30) = 1.61,
p = .18, ŋp
2 = .24, were found.
Criterion and convergent validity
Table 4 summarizes the correlations between the
QoLISSY scales and the KIDSCREEN-10 Index. For
patient-reports, moderate positive correlations were
found between the disease-specific and generic HRQOL,
with coefficients ranging from r = .28 (belief scale at T1)
to r = .46 (coping scale at T1); for parent-reports, weak
to moderate positive correlations were found, with coef-
ficients ranging from r = .13 (belief scale at T1) to r = .41
(emotional scale at baseline). Regarding convergent
Table 1 Sample characteristics at baseline (T0) and after 1 year of hGH treatment (T1)
T0 (N = 154) T1 (N = 130)
IGHD (N = 65) SGA (N = 58) ISS (N = 31) IGHD (N = 60) SGA (N = 48) ISS (N = 22)
Age (yrs.) M (SD)a,b 8.09 (3.34) 6.55 (2.64) 9.45 (3.49) 9.22 (3.37) 7.81 (2.76) 10.68 (3.24)
Missing, n (%) – – – 1 (1.7) – –
Age group, N (%)
4–7 years 34 (52.3) 41 (70.7) 7 (22.6) 26 (43.3) 28 (58.3) 4 (18.2)
8–12 years 22 (33.8) 15 (25.9) 16 (51.6) 22 (36.7) 18 (37.5) 10 (45.5)
13–17 years 9 (13.8) 2 (3.4) 8 (25.8) 11 (18.3) 2 (4.2) 8 (36.4)
Missing (%) – – – 1 (1.7) – –
Gender, N (%)
Male 48 (73.8) 33 (56.9) 16 (51.6) 44 (73.3) 29 (60.4) 11 (50.0)
Female 17 (26.2) 25 (43.1) 15 (48.4) 16 (26.7) 19 (39.6) 11 (50.0)
Height (cm), M (SD)c 117.11 (17.44) 108.01 (13.45) 126.24 (18.86) 127.04 (17.53) 118.89 (13.65) 132.48 (17.77)
Missing (%) – 1 (1.7) 1 (3.2) 2 (3.3) 2 (4.2) 1 (4.5)
Height deviation (SDS), M (SD)d − 2.61 (.61) −2.65 (0.63) − 2.11 (.51) − 1.91 (.64) −2.05 (.67) − 2.06 (.73)
Missing (%) 1 (1.5) 1 (1.7) 1 (3.2) 2 (3.3) 5 (10.4) 1 (4.5)
Height deviation group, N (%)e
Normal height (< − 2 SDS) 11 (16.9)** 6 (10.3)** 13 (41.9)** 32 (53.3) 23 (47.9) 10 (45.5)
Short stature (≥ − 2 SDS) 54 (83.1) 51 (87.9) 17 (54.8) 25 (41.7) 23 (47.9) 11 (50.0)
Missing (%) – 1 (1.7) 1 (3.2) 3 (5.0) 2 (4.2) 1 (4.5)
Treatment length (months), M (SD) – – – 12.64 (1.93) 12.25 (2.43) 12.73 (2.76)
Missing (%) – – – 1 (1.7) – –
Note: M= Mean, SD = Standard deviation, SDS=Standard deviation score, IGHD = idiopathic growth hormone deficiency, SGA = short for gestational age, ISS =
idiopathic short stature, T0 = baseline, T1 = 12 month after start of hGH treatment
a children with SGA were significantly younger than children with IGHD or ISS at baseline (F(2) = 9.21, p < .01)
b children with SGA were significantly younger than children with ISS at T1 (F(2) = 6.74, p < .01)
c children with SGA were significantly smaller than children with ISS or IGHD at baseline (F(2) = 12.74, p < .01) and at T1 (F(2) = 5.59, p < .01)
d children with SGA and IGHD were significantly the smallest compared to children with ISS at baseline (F(2) = 8.70, p < .01)
e a significant higher percentage of children with ISS already reached a normal height at T0 (χ(2)
2 = 13.92, p < .01)
* p < .05; ** p < .01, two-tailed
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validity as assessed with inter-correlations among the
QoLISSY subscales, moderate to strong positive correlations
were found across the physical, social, emotional and beliefs
scales, in both patient- and parent-reports, as well as across
the future and effects on parents scales of the parent-reported
version. In both patient- and parent-reports, the coping scale
was weakly to moderately positively correlated with all
QoLISSY scales and with the total score, while the treatment
scale did not correlate significantly with any of the scales nor
with the total score. However, it needs to be noted, that the
treatment subscale was only applied in the treated sample in-
cluding children with IGHD and SGA, and the other
QoLISSY subscales are being tested in a more heterogeneous
sample, including non-treated patients with ISS.
Known-groups validity
The MANCOVA for patient-reported QoLISSY scales,
controlling for children’s age and height deviation group,
Table 2 Descriptive statistics and reliability for the QoLISSY scales across all diagnoses
Descriptive Statistics Reliability
Patient-report N M SD Skewness Kurtosis Floor (%) Ceiling (%) N α
Physical T0 65 55.96 26.66 −.32 −.82 4.6 .00 65 .83
T1 70 61.50 25.36 −.48 −.63 .00 .00 64 .83
Social T0 66 52.94 26.84 −.20 −.91 4.5 .00 62 .87
T1 70 62.15 23.88 −.72 −.17 1.4 .00 62 .82
Emotional T0 65 53.41 27.00 −.06 −1.18 .00 1.5 58 .88
T1 69 62.49 24.65 −.61 −.27 1.4 1.4 66 .87
Coping T0 66 62.87 21.95 −.47 −.65 .00 .00 65 .82
T1 66 58.81 16.45 .02 −1.07 .00 1.5 63 .65
Beliefs T0 66 49.62 32.07 −.10 −1.21 10.6 4.5 66 .88
T1 68 51.56 31.75 .09 −1.20 8.8 8.8 68 .86
Treatment T0 – – – – – – – – –
T1 50 60.52 17.64 −.49 −.33 .00 .00 44 .83
Total Scorea T0 64 54.11 24.96 −.24 −.89 .00 .00 54 .95
T1 69 61.82 22.87 −.60 −.36 .00 .00 54 .94
Parent-report N M SD Skewness Kurtosis Floor (%) Ceiling (%) N α
Physical T0 150 52.57 26.74 −.09 −1.06 1.3 1.3 146 .88
T1 126 58.12 25.64 −.23 −1.19 .00 2.4 117 .89
Social T0 150 51.43 24.94 −.05 −.94 2.7 .00 129 .86
T1 125 57.25 25.68 −.35 −.86 1.6 0.8 113 .87
Emotional T0 150 52.34 25.95 −.06 −.87 1.3 2.0 143 .89
T1 125 58.25 24.65 −.27 −.68 .80 2.4 116 .87
Coping T0 135 50.97 17.86 .20 −.47 .00 .00 125 .75
T1 115 51.08 18.00 −.09 −.45 .00 1.7 109 .78
Beliefs T0 144 54.99 29.41 −.12 −1.05 6.3 9.0 142 .88
T1 123 55.95 30.10 −.16 −1.08 4.9 10.6 123 .88
Treatment T0 – – – – – – – – –
T1 95 59.76 18.90 .33 −.62 .00 .00 81 .87
Future T0 140 58.43 30.31 −.18 −1.07 4.3 12.9 140 .88
T1 119 62.17 29.09 −.46 −.89 3.4 11.8 111 .88
Effects on parents T0 148 52.54 22.88 .24 −.75 .00 0.7 139 .86
T1 125 58.37 23.04 −.15 −.65 .00 2.4 112 .86
Total Scorea T0 147 52.06 23.73 .06 −.92 .00 .00 123 .94
T1 125 57.96 23.54 −.28 −.84 .00 .00 103 .95
Note: M =Mean, SD = Standard deviation, α = Cronbach’s alpha value, T0 = baseline, T1 = 12 month after start of hGH treatment
a Sum of the scales physical, social, emotional
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yielded no significant multivariate effects of treatment
status on QoLISSY scales at baseline, Pillai’s trace = .17,
F(5, 54) = 2.36, p = 0.052, ŋp
2 = .17. However, a significant
univariate effect was found in the physical, social and
emotional scale, with children who were about to start
treatment reporting a significantly lower HRQOL at
baseline compared to the ISS children not receiving
treatment. A significant univariate effect was also found
for the total score F(1, 158) = .7.44, p = .008, ŋp
2 = .11 (see
Table 5).
Regarding parent-reports a significant multivariate ef-
fect of treatment status was found on QoLISSY scales,
Pillai’s trace = .12, F(7, 117) = 2.31, p = 0.03, ŋp
2 = .12. Sub-
sequent univariate analysis showed significant differ-
ences between the treated and the untreated group in
the physical, social, emotional, coping and future domain,
with parents of children in the treated group reporting a
lower HRQOL in these domains at baseline, compared to
parents of children who remained untreated. In addition,
a significant effect of treatment status was found in the
total score, F(1, 141) = 7.70, p = .006, ŋp
2 = .05, with parents
of treated children reporting significantly lower HRQOL
than parents of children with ISS (p < .01) (see Table 5).
After treatment, no significant multivariate effect of treat-
ment status on QoLISSY scales were found in child-report,
Pillai’s trace = .07, F(5, 54) = .85, p= 0.51, ŋp
2 = .07, or for the
total score, F(1, 62) = .002, p= .966, ŋp
2 = .00. Also the
parent-reports yielded no significant multivariate effect of
treatment status on QoLISSY scales, Pillai’s trace = .064,
F(7, 95) = .93, p = 0.48, ŋp
2 = .06. However, a significant
effect of the physical scale was found in the univariate
analysis in the parent-report F(1, 101) = 5.094, p = .02,
ŋp
2 = .04. The univariate analysis for the total score
revealed no significant effect, F(1, 114) = 3.21, p = .07,
ŋp
2 = .02.
Regarding effects of height deviation groups (children/
adolescents with a height deviation ≥ − 2 SD vs. chil-
dren/adolescents who already achieved normal height at
the time of assessment) at baseline, the MANCOVA,
controlling for children’s age and diagnosis (GHD or
SGA vs. ISS), showed no significant multivariate effects
on the QoLISSY scales for patient-reports, Pillai’s trace = .09,
F(5, 54) = 1.066, p= 0.38, ŋp
2 = .09, and for parent-reports, Pil-
lai’s trace = .06, F(7, 117) = 1.18, p= .32, ŋp
2 = .06. Neverthe-
less, a significant univariate effect was found in the social
scale for patient-reports, F(1, 58) = 4.89, p= .03, ŋp
2 = .07, and
for parent-reports, F(1, 123) = 5.55, p= .02, ŋp
2 = .04, with
short statured children scoring significantly lower in this do-
main. The univariate analyses are presented in Table 6. In
addition, the univariate ANCOVA for the QoLISSY total
score showed no significant differences between children/ad-
olescents with current short stature and their peers who
achieved normal height for patient-reports, F(1, 58) =
3.87, p = .06, ŋp
2 = .06, and for parent-reports, F(1, 141) =
3.44, p = .06, ŋp
2 = .02.
After treatment, no significant multivariate effects
of height deviation group on QoLISSY scales, Pillai’s
trace = .03, F(5, 54) = .33, p = 0.88, ŋp
2 = .03, or for the
total score F(1, 62) = .01, p = .91, ŋp
2 = .00 were found
in patient-report. Also the parents-report yielded no
Table 3 Inter-rater reliability: Intraclass Correlation Coefficients and ANCOVA for repeated measures
Patient-Reports (N = 55) Parent-reports (N = 55) ANCOVA for repeated measures ICC [CI]
M (SD) M (SD) F p Ŋp2
Physical T0 56.74 (26.59) 48.94 (24.71) 2.36 .13 .04 .56** [.36–.71]
T1 59.60 (25.93) 51.10 (24.86) .01 .93 .00 .44** [.23–.62]
Social T0 54.27 (26.65) 43.32 (23.57) 2.91 .09 .05 .74** [.60–.83]
T1 62.59 (24.75) 48.38 (26.62) .22 .64 .01 .44** [.22–.61]
Emotional T0 53.76 (26.79) 41.88 (22.36) .36 .55 .01 .67** [.50–.78]
T1 63.49 (23.32) 49.05 (24.73) .06 .80 .00 .58** [.39–.72]
Coping T0 62.18 (22.34) 52.42 (18.90) 2.87 .10 .05 .35** [.11–.56]
T1 60.90 (16.22) 48.81 (14.82) 4.98 .03 .13 .29* [.03–.50]
Beliefs T0 48.75 (32.00) 46.02 (30.37) .02 .89 .00 .61** [.44–.75]
T1 51.25 (32.68) 48.75 (30.40) .78 .38 .02 .56** [.36–.70]
Treatment T0 – – – – – –
T1 62.88 (16.99) 60.10 (16.88) 5.38 .03 .13 .45** [.19–.65]
Total Score a T0 55.91 (24.46) 44.81 (22.12) 2.39 .13 .04 .74** [.60–.83]
T1 62.58 (22.95) 53.53 (24.03) .01 .92 .00 .55** [.36–.70]
Note: M =Mean, SD = Standard deviation, F=F-value, p = P-value, Ŋp2 = partial eta square, ICC=Intraclass correlation coefficient (two-way mixed model, absolute
agreement, 95% confidence interval [CI], T0 = baseline, T1 = 12 month after start of hGH treatment
* p < .05; ** p < .01, two-tailed
a sum of the scales physical, social, emotional
Bloemeke et al. Health and Quality of Life Outcomes           (2019) 17:49 Page 7 of 15
significant multivariate effect of height deviation group on
QoLISSY scales, Pillai’s trace = .05, F(7, 95) = .82, p = 0.56,
ŋp
2 = .05, or for the total score F(1, 114) = .03, p = .85,
ŋp
2 = .00.
Responsiveness
The repeated measures MANCOVA for the patient-reported
QoLISSY scales, controlling for the effects of age and treat-
ment length, yielded no significant multivariate main effects
of time, Pillai’s trace = .18, F(5, 43) = 1.84, p= .13, ŋp
2 = .18, or
treatment status, Pillai’s trace = .13, F(5, 43) = 1.33, p= .27, ŋp
2
= .13. However, the multivariate interaction effect between
time and treatment status was statistically significant, Pillai’s
trace = .27, F(5, 43) = 3.24, p= .01, ŋp
2 = .27. The subsequent
univariate analyses (Table 7) revealed that treated
children/adolescents in the intervention group (diag-
noses IGHD or SGA) reported a significant increase
of physical, social and emotional HRQOL from base-
line assessment throughout one year of treatment,
while untreated patients of the control group (diagno-
sis ISS) reported a decrease in these HRQOL domains
over time.
Table 4 Pearson Correlation coefficients between the QoLISSY scales and the KIDSCREEN-10 Index and QoLISSY interscale-correlations
Patient-reports KIDSCREEN-10 1 2 3 4 5 6
1. Physical T0 .41** –
T1 .30* –
2. Social T0 .38** .84** –
T1 .32** .82** –
3. Emotional T0 .43** .71** .79** –
T1 .30* .75** .82** –
4. Coping T0 .42** .29* .28** .46** –
T1 .46** .22 .31* .35** –
5. Beliefs T0 .38** .61** .65** .81** .30* –
T1 .28* .60** .66** .76** .34** –
6. Treatment T0 – – – – – – –
T1 .43** .14 .02 −.03 .20 −.12 –
QoLISSY Total Score a T0 .44** .92** .95** .90** .38** .75** –
T1 .33** .92** .94** .92** .33** .73** .05
Parents-reports KIDSCREEN-10 1 2 3 4 5 6 7 8
1. Physical T0 .27** –
T1 .28** –
2. Social T0 .31** .77** –
T1 .35** .81** –
3. Emotional T0 .41** .69** .85** –
T1 .27** .73** .86** –
4. Coping T0 .26** .14 .16 .25** –
T1 .23* .26** .28** .35** –
5. Beliefs T0 .34** .56** .59** .69** .16 –
T1 .13 .60** .62** .67** .24* –
6. Treatment T0 – – – – – – –
T1 .27* .04 −.02 −.06 .14 −.13 –
7. Future T0 .27** .62** .70** .73** .22* .70** – –
T1 .15 .58** .67** .70** .21* .68** −.07 –
8. Effects on parents T0 .36** .55** .60** .60** .25** .56** – .58** –
T1 .22* .62** .65** .66** .25** .63** −.02 .74** –
QoLISSY Total Score a T0 .36** .89** .94** .92** .20* .68** – .73** .63**
T1 .33** .91** .96** .93** .32** .86** −.01 .70** .69**
Note: * p < .05; ** p < .01, two-tailed, T0 = baseline, T1 = 12month after start of hGH treatment
a sum of the scales physical, social, emotional
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These results of differences between the treated and
the untreated sample were supported by the univariate
repeated measures ANCOVA for the QoLISSY total
score, which also revealed a significant interaction effect
between time and treatment status, F(1, 50) = 9.72, p < .01,
ŋp
2 = .16, while controlling for the effects of age at base-
line, F(1, 50) = .03, p = .86, ŋp
2 = .00, and treatment length,
F(1, 50) = 3.97, p = .05, ŋp
2 = .07.
Apart from the significant results in patient-reports,
the parent-reports revealed no multivariate main effects
Table 5 Univariate analyses of covariance between treatment status at baseline (T0)
Treated (IGHD/SGA) Untreated (ISS)
Patient-reports M (SD) (N = 40) M (SD) (N = 22) F p Ŋp2
Physical 48.33 (28.00) 69.88 (17.86) 8.44 .005 .12
Social 46.99 (29.03) 64.85 (18.86) 4.72 .03 .07
Emotional 47.35 (25.13) 65.76 (26.67) 5.76 .02 .09
Coping 62.50 (21.40) 62.38 (24.30) .01 .92 .00
Beliefs 43.28 (29.70) 61.36 (32.76) 3.57 .06 .05
Total Score a 47.56 (25.74) 66.83 (18.04) 7.445 .008 .11
Parents-reports M (SD) (N = 99) M (SD) (N = 28) F p Ŋp2
Physical 47.84 (25.97) 65.47 (24.05) 8.91 .003 .06
Social 47.40 (24.79) 58.72 (23.79) 4.59 .03 .03
Emotional 48.42 (24.63) 57.86 (26.41) 4.69 .03 .03
Coping 49.10 (16.99) 58.22 (19.56) 3.95 .04 .03
Beliefs 52.52 (29.25) 58.25 (33.29) 1.39 .24 .01
Future 53.93 (30.21) 68.57 (26.62) 8.12 .005 .06
Effects on parents 49.61 (22.34) 56.69 (22.05) 1.48 .22 .01
Total Score a 49.91 (23.54) 61.50 (22.58) 7.70 .006 .05
Note: M =Mean, SD = Standard deviation, F=F-value, p = P-value, Ŋp2 = partial eta square, IGHD = idiopathic growth hormone deficiency, SGA = short for
gestational age, ISS = idiopathic short stature
Children’s age and height deviation group were included as covariates
a sum of the scales physical, social, emotional
Table 6 Univariate analyses of covariance between height deviation groups at baseline (T0)
Short stature (≤ −2 SDS) Normal height (> −2 SDS)
Patient-reports M (SD) (N = 47) M (SD) (N = 15) F p Ŋp2
Physical 52.48 (26.83) 66.94 (24.47) 3.43 .06 .05
Social 49.11 (27.72) 66.58 (20.79) 4.89 .03 .07
Emotional 51.07 (26.70) 62.71 (26.82) 1.80 .18 .03
Coping 61.70 (21.52) 64.83 (25.15) .12 .72 .00
Beliefs 46.14 (33.01) 60.83 (25.38) 2.29 .13 .03
Total Score a 50.89 (25.27) 65.41 (21.03) 3.87 .06 .06
Parents-reports M (SD) (N = 101) M (SD) (N = 26) F p Ŋp2
Physical 49.95 (26.36) 58.65 (26.43) 1.37 .24 .01
Social 47.08 (24.33) 60.85 (24.67) 5.55 .02 .04
Emotional 48.05 (25.07) 60.04 (24.03) 3.74 .06 .03
Coping 49.92 (17.37) 55.76 (19.56) 1.11 .29 .01
Beliefs 52.72 (30.59) 57.93 (28.59) .52 .46 .00
Future 54.65 (30.08) 66.92 (28.07) 2.59 .11 .02
Effects on parents 50.27 (22.65) 54.68 (21.41) .52 .47 .00
Total Score a 50.32 (23.42) 60.28 (23.76) 3.44 .06 .02
Note: M =Mean, SD = Standard deviation, SDS=Standard deviation score, F=F-value, p = P-value, Ŋp2 = partial eta square
Children’s age and height deviation group were included as covariates
a sum of the scales physical, social, emotional
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of treatment status, Pillai’s trace = 0.14, F(7, 88) = 2.07,
p = .06, ŋp
2 = .14, or interaction effects between time
and treatment status, Pillai’s trace = .06, F(7, 88) = .85,
p = .55, ŋp
2 = .06. But there was a significant multivariate
main effect of time, Pillai’s trace = .19, F(7, 88) = 2.91, p = .01,
ŋp
2 = .19, which revealed a significant improvement from
baseline to T1 on the effects on parents scale, for both inter-
vention and control groups, F(1, 94) = 7.75, p < .01, ŋp
2 = .08.
The univariate analyses for the interaction effect are
presented in Table 7. Although differences were not statisti-
cally significant the results demonstrate a trend that
HRQOL scores improved in all QoLISSY domains in the
treated sample, while scores decreased in the social, coping,
beliefs, future, effects on parents scale and in the total score
in the untreated sample.
Also the ANCOVA for the parent-reported QoLISSY
total score yielded no significant main effects of time,
F(1, 118) = 1.02, p = 0.31, ŋp
2 = .01, or interaction effects
Table 7 HRQOL changes from baseline (T0) and 1-year follow-up (T1) between treated and untreated patients
Treated (IGHD/SGA) Untreated (ISS)
Patient-reports M (SD) (N = 33) M (SD (N = 18) F p Ŋp2
Physical T0 48.99 (26.96) 69.91 (18.22) 8.51 < .01 .15
T1 62.65 (22.85) 61.94 (27.57)
Social T0 45.67 (26.64) 66.42 (20.42) 14.76 < .01 .24
T1 62.04 (25.86) 58.51 (23.70)
Emotional T0 47.06 (24.86) 70.71 (26.56) 11.68 < .01 .20
T1 61.24 (23.29) 62.18 (26.80)
Coping T0 60.98 (22.29) 67.78 (21.62) 2.44 .13 .05
T1 60.56 (16.19) 57.08 (18.03)
Beliefs T0 41.86 (30.03) 68.06 (31.21) 3.23 .08 .06
T1 46.59 (33.88) 56.60 (28.72)
Total score a T0 48.88 (24.17) 69.01 (19.50) 9.72 < .01 .16
T1 61.60 (22.88) 60.88 (24.20)
KIDSCREEN-10 Index T0 54.80 (12.06) 51.93 (9.10) 1.06 .30 .02
T1 55.80 (10.58) 55.66 (13.89)
Parents-reports M (SD) (N = 78) M (SD) (N = 20) F p Ŋp2
Physical T0 46.78 (25.54) 62.50 (25.90) .14 .71 .00
T1 54.11 (25.04) 63.92 (26.11)
Social T0 48.20 (24.64) 58.62 (24.46) .79 .38 .01
T1 55.49 (25.73) 58.50 (27.39)
Emotional T0 47.88 (24.37) 58.19 (23.58) .85 .36 .01
T1 55.89 (24.63) 60.16 (27.56)
Coping T0 48.30 (17.03) 59.89 (21.49) 1.56 .22 .02
T1 50.42 (15.68) 55.18 (24.01)
Beliefs T0 51.92 (28.97) 61.25 (32.23) .24 .62 .00
T1 50.88 (29.08) 57.19 (36.01)
Future T0 52.05 (30.38) 70.25 (25.31) 3.33 .07 .03
T1 59.73 (28.37) 63.56 (29.28)
Effects on parents T0 49.48 (22.10) 59.84 (24.41) .25 .62 .00
T1 55.62 (21.70) 58.99 (27.36)
Total score a T0 50.56 (23.57) 60.97 (22.46) 1.33 .25 .01
T1 57.34 (23.31) 60.63 (25.05)
KIDSCREEN-10 Index T0 50.90 (10.16) 51.75 (7.84) 2.71 .10 .03
T1 51.75 (7.84) 48.56 (12.11)
Note: Analysis: Univariate analyses of covariance. M =Mean, SD = Standard deviation, F=F-value, p = P-value, Ŋp2 = partial eta square, IGHD = idiopathic growth
hormone deficiency, SGA = short for gestational age, ISS = idiopathic short stature, T0 = baseline, T1 = 12 month after start of hGH treatment
a sum of the scales physical, social, emotional
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between time and treatment status, F(1, 118) = 1.33, p = 0.25,
ŋp
2 = .01, while controlling for the effects of age at baseline,
F(1, 118) = 16.94, p < .01, ŋp
2 = .13, and treatment length,
F(1, 118) = .83, p = .37, ŋp
2 = .01. Nevertheless, a signifi-
cant main effect of treatment status was found for the
parent-reported QoLISSY total score, F(1, 118) = 5.83,
p = .02, ŋp
2 = .05. Independently of time of assess-
ment, parents of treated children reported a lower
HRQOL than parents of untreated children. The
KIDSCREEN-10 Index, revealed no significant main ef-
fects of the interaction between time and treatment status
in child, Pillai’s trace = .02, F(1, 49) = 1.06, p = .31, ŋp
2 = .02,
and parent-report, Pillai’s trace = .03, F(1, 88) = 2.71, p = .10,
ŋp
2 = .03.
The repeated measures MANCOVA, controlling for
the effects of age and treatment length, yielded no sig-
nificant interaction effect between time and height devi-
ation groups at after 1-year of treatment in patient,
Pillai’s trace = .054, F(5, 40) = .458, p = .80, ŋp
2 = .054, and in
parent report, Pillai’s trace = .023, F(7, 84) = .278, p = .96,
ŋp
2 = .023. Also the univariate repeated measures
ANCOVA for the QoLISSY total score, revealed no signifi-
cant interaction effect between time and height deviation
groups after 1-year of treatment in child, F(1, 47) = 0.00,
p = .92, ŋp
2 = .00, and parent report, F(1, 112) = .624,
p = 0.431, ŋp
2 = .00, while controlling for age at
baseline and treatment length. Univariate analysis
are presented in Table 8.
Finally, the analysis of the relationship between height
change and the HRQOL change prove significant posi-
tive correlation between height SDS increase (height dif-
ference between T1 and baseline) and total HRQOL
gain (difference between QoLISSY total score at T1 and
at baseline) in both the child (r = − 0.38, p ≤ 0.01) and
parent-reports (r = − 0.18, p = 0.04). This suggests that a
larger increase in body height is associated with greater
improvement in the total HRQOL which reflects phys-
ical, social and emotional HRQOL.
Discussion
Among the different health outcomes that can be mea-
sured, HRQOL has become a universally recognized
endpoint to assess because of the potential of HRQOL
instruments to reflect treatment benefits that affects pa-
tients actual value [7]. However, for rare conditions such
endocrine short stature, use of generic HRQOL instru-
ments is limited. Although generic instruments are
well-validated and allow for comparison across popula-
tions, they often fail to detect small, but clinically signifi-
cant changes over time in HRQOL due to the absence of
disease-specific aspect of affected patients’ lives that
have an impact on their HRQOL [7]. This aspect is sup-
ported by the results of this study. While the generic
KIDSCREEN instrument is not able to detect changes in
HRQOL in this sample, the disease-specific QoLISSY
questionnaire detects changes of HRQOL within the
course of hGH treatment between the treated and the
untreated group in the patient-report. Treated children/
adolescents who are diagnosed with IGHD or SGA re-
ported a significant increase of physical, social and emo-
tional HRQOL from baseline assessment throughout
one year of treatment, while untreated patients of the
control group diagnosed with ISS reported a decrease in
these HRQOL domains over time. However, effect sizes
for these results were rather small. Although differences
were not statistically significant in parent-report, the re-
sults demonstrate a trend that parents of children who
were treated with hGH reported an increase in their
children’s HRQOL, while parents of children who were
not treated reported a decrease in most domains
throughout treatment. Besides, results of the correlation
analysis between changes in the QoLISSY total score and
height SDS gain shows that increased height results in
improved physical, social and emotional HRQOL.
Similar outcomes were found in studies, showing that
disease-specific instruments are able to detect changes
in HRQOL in populations affected by rare health condi-
tions. Lem et al. (2012) also revealed, that only the
disease-specific instrument (TACQOL-S) showed im-
provement in HRQOL in treated children with hGH
compared to untreated children, while the generic in-
strument did not reveal any HRQOL changes. Thus,
when measuring the impact of treatment and to capture
the change over time, a psychometric solid and disease-
specific instrument is needed [7, 48].
Results of the repeated measures MANCOVA testing
the HRQOL changes from baseline and 1-year
follow-up (T1) between patients who reached normal
height and patients with current short stature at T1
showed no significant results in the current study. This
might indicate that reaching a normal height, either be-
cause of treatment or because of normal development,
did not have a significant effect on the overall HRQOL
or any of its specific domains. Although the QoLISSY
questionnaire was not able to detect these longitudinal
HRQOL changes from baseline to 1-year after treat-
ment between patients who reached normal height and
patients with current short stature after treatment (see
Table 8), the questionnaire was able to detect differ-
ences between height deviation groups at baseline
(Table 6 – social HRQOL in self- and parent-report).
On the one hand, this might indicate, that it is very
likely that the change in HRQOL from baseline to
1-year after treatment is not depending on the treat-
ment or the increase in height, on the other hand, the
questionnaire might lack sensitivity to detect clinically
significant changes and that further studies are neces-
sary to clarify this issue.
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In addition to the debate between using generic or
disease-specific HRQOL instruments, another aspect
under discussion is the benefits of using self-reports vs.
proxy-reports (ex. parents) when assessing HRQOL in
pediatric populations. Self-reports are generally the pre-
ferred source of HRQOL data because of the concern of
inaccurate reporting by proxies [12, 49]. However, when
comparing the reported data between the child- and
parent-report of the QoLISSY instrument in this study,
analyses of ICC values indicated moderate parent-child
agreement, except for the coping and treatment subscale,
where the highest disagreement was observed. These
findings underline, that especially psychosocial aspects
of children’s HRQOL (such as coping strategies) cannot
be observed and reported by a proxy as reliably as more
obvious aspects (e.g. physical aspects) [12, 50, 51]. Thus,
this study provides on the one hand support to use both
self- and observed-reported HRQOL data in order to
gain a comprehensive and more complementary view of
the child’s experience of illness. On the other hand,
when using child reported data in longitudinal studies,
the cognitive development process of the children [52]
needs to be considered. Opinions, feelings and attitudes
might change quickly resulting in score changes that in-
fluences the responsiveness when assessing HRQOL.
Hence, Coq et al. (2000) recommended the use of
Table 8 HRQOL changes from baseline (T0) and 1-year follow-up (T1) between patients who reached normal height and patients
with current short stature after 1-year of treatment
Short stature (≤ −2 SDS) Normal height (> −2 SDS)
Patient-reports M (SD) (N = 28) M (SD) (N = 20) F p Ŋp2
Physical T0 59.38 (24.63) 51.88 (29.79) 1.137 .29 .02
T1 61.61 (20.95) 63.92 (29.16)
Social T0 51.51 (23.33) 53.48 (31.68) .075 .78 .00
T1 58.04 (25.29) 63.86 (25.16)
Emotional T0 55.72 (28.72) 54.38 (27.59) .024 .87 .00
T1 61.90 (22.93) 60.33 (27.59)
Coping T0 61.25 (20.05) 64.25 (25.59) .00 .94 .00
T1 57.68 (17.36) 60.68 (17.06)
Beliefs T0 52.46 (36.06) 50.00 (30.28) .03 .85 .00
T1 50.00 (32.59) 49.38 (34.11)
Total score a T0 55.42 (22.94) 55.16 (28.06) 0.10 .92 .00
T1 61.15 (21.17) 61.24 (26.34)
Parents-reports M (SD) (N = 41) M (SD) (N = 53) F p Ŋp2
Physical T0 54.96 (24.11) 47.88 (27.56) .65 .41 .00
T1 57.22 (24.03) 55.72 (27.00)
Social T0 52.68 (24.44) 49.95 (25.12) .01 .90 .00
T1 57.58 (24.58) 56.32 (27.49)
Emotional T0 51.26 (25.17) 50.41 (23.96) .25 .61 .00
T1 56.33 (25.13) 58.37 (25.52)
Coping T0 52.57 (20.60) 50.10 (15.67) .19 .66 .00
T1 54.37 (18.18) 50.07 (16.53)
Beliefs T0 57.93 (29.94) 50.71 (29.99) .00 .97 .00
T1 57.01 (31.78) 50.71 (29.38)
Future T0 62.32 (28.33) 52.74 (30.96) .64 .42 .00
T1 64.27 (26.77) 59.06 (29.94)
Effects on parents T0 55.62 (23.75) 49.11 (22.06) .06 .79 .00
T1 58.94 (21.70) 54.70 (24.18)
Total score a T0 55.00 (22.78) 50.61 (23.73) .62 .43 .00
T1 58.88 (22.09) 57.82 (24.70)
Note: Analysis: Univariate analyses of covariance. M =Mean, SD = Standard deviation, F=F-value, p = P-value, Ŋp2 = partial eta square, T0 = baseline, T1 = 12 month
after start of hGH treatment
a sum of the scales physical, social, emotional
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parent-reports in longitudinal intervention studies [53].
Also in this study, cognitive development changes might
have influenced the responsiveness positively, since the
child-report yielded significant changes over time in
HRQOL, while the parent-report did not.
Internal consistency, as assessed by Cronbach’s alpha,
was satisfactory in all scales with α > .70, except for the
coping scale at T1 in child-report (α = .65). The Cron-
bach’s alpha values found in this study were similar to
those observed in the original QoLISSY study [33], with
the exception of the coping scale in the child-report, in
which α was > .70 in the original study. A possible ex-
planation for the inadequate Cronbach alpha value for
the coping scale might be that the item content of this
scale may be irrelevant or not correctly portray the ex-
perience of a patient population that receives treatment
because of their short stature, thus leading to inconsist-
ent responses. Furthermore, the lower Cronbach’s alpha
value might suggest a poorer interrelatedness between
the items of this scale, reflecting that coping is a hetero-
geneous construct, consisting of many facets and various
coping strategies that are difficult to capture within one
scale. Besides, the lower value might reflect difficulties
in understanding item wordings, which might have let to
inconsistent responses.
Also the scale inter-correlation values of the QoLISSY
questionnaire were very similar to the values found in
the original development and validation study of the
QoLISSY questionnaire [9], including nonsignificant or
low inter-correlations of the coping and treatment scales
with all other scales of the QoLISSY instrument. With the
exception of a few scales, most QoLISSY scales showed
significant moderate correlations (r > .30) with the
KIDSCREEN-10 Index, supporting the criterion validity of
the instrument and that both instruments measure the
construct of HRQOL. Nevertheless, the moderate correla-
tions also indicate towards a discrepancy between both
measures, which further supports the importance of using
disease-specific instruments that are able to catch unique
aspects experienced by the affected people that generic in-
struments would miss.
Comparisons of HRQOL scores between participants that
were treated with hGH compared to participants that were
not treated demonstrated known-group validity for the total
score in child- and parent-report, with children who were
about to start treatment and parents of these children re-
ported a lower HRQOL, compared to children who
remained untreated at baseline. After treatment, no signifi-
cant differences in HRQOL between the treated and the un-
treated sample were found in child- and parent-reports.
Contradictory to results of known-group validity analysis
found in the original development and validation study of
the QoLISSY questionnaire [47], QoLISSY was not able to
distinguish between the severity level of short stature (height
SDS) at both points of measurement in the current sample.
This might be due to the fact, that at baseline most children
in the sample were short statured (height SDS ≤ − 2). Fur-
thermore, this study was designed as a longitudinal study
and thus a cross-sectional analysis as conducted for the
known-group validity might be not as appropriate as a re-
sponsiveness analysis that combines both measurement
points. As already discussed above, QoLISSY proves to be
able to detect changes in child reported HRQOL within the
course of treatment.
One limitation within this study is that a confirmatory
factor analysis was not calculated because of the small sam-
ple size. Nevertheless, the factor structure of the QoLISSY
instrument was previously ascertained for identifying the
final scale structure of the instrument. The initial confirma-
tory factor analysis produced the three core quality of life
domains (physical, social, emotional) which composed to
the QoLISSY total score, while the other domains were
used as determinants [33]. In general, the smaller sample
size and drop-out rate might have biased the results. How-
ever, keeping in mind that endocrine short stature is a rare
disease, this study included a relatively large sample size.
Still, the sample is very selective because all of them con-
tacted growth clinics seeking for treatment options. There-
fore, it can be assumed that the sample is highly motivated
and not necessarily representative of the overall target
population. Since this study was an observational study
based on “natural” treated and untreated groups complying
with standard clinical practice and appropriate prescribing
guidelines (determined by European Medicine Agency), we
were not able to include a normal statured, age-matched
not treated control group with IGHD or SGA for compari-
son as this would be considered unethical. Furthermore,
the sample description (Table 1) shows that some patients,
especially patients in the control group with the diagnosis
ISS, already reached a normal height by definition (< − 2
SDS) at baseline. We used the common German reference
values of Kromeyer-Hausschild et al. (2001) to calculate the
height SDS, which might resulted in slightly different scores
than the clinician used when diagnosing the patient. Thus,
the sample included also a few patients who had normal
height at baseline, which might have biased the results. In
general, significant results should be interpreted with cau-
tion because of the small sample and small effect sizes. An-
other point is, that due to the design of the study our
responsiveness analyses were limited to 12months of treat-
ment. However, greater changes in HRQOL might also ap-
pear after some time having finished the treatment.
Conclusions
These psychometric analyses of the QoLISSY question-
naire support the reliability, validity, and ability of the in-
strument to detect change over time and thus support its
usefulness to measure HRQOL in a pediatric endocrine
Bloemeke et al. Health and Quality of Life Outcomes           (2019) 17:49 Page 13 of 15
population receiving hGH treatment. Hence, in addition
to clinical endpoints, HRQOL can also be adequately
assessed within a clinical setting. Further use of the
QoLISSY in longitudinal studies may provide greater
insight into the clinical meaningfulness of changes in
HRQOL scores.
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